Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of PG-102 (MG12) in obesity and type 2 diabetes mellitus
KCT0009978Phase 2Completed
- Sponsor
- PROGEN
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of PG-102 in obesity, type 2 diabetes mellitus (T2DM), sponsored by PROGEN. Started Dec 2024; status: completed.
02
Drugs
PG-102
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0009978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009978.